More on RHHBY

- Summary
- Chart
- Profile
- Historical

Data

- Ratings (2.7 Score)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Roche (OP:RHHBY)
Delayed: 41.58 --0 (-0%)
Prev. Close $41.58  
Open$41.58 
52 Wk High$35.13 
52 Wk Low$28.10 
Day High$41.58 
Day Low$41.58 
P/E N/A  
EPS$0.00 
Volume112 

Friends, Peers and Foes (?): RO, ROG, ROG:SW, 0QOK, CHGCY (more...)

May 11, 2021 01:00 AM Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer
Apr 28, 2021 04:17 PM FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for Previously Untreated Metastatic Bladder Cancer
Apr 27, 2021 06:32 PM FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
Apr 25, 2021 07:30 PM CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 25, 2021 05:09 AM Roche Holding (ROG:SW) (RHHBY) PT Lowered to CHF432 at Goldman Sachs
Apr 16, 2021 01:00 AM  New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
Apr 15, 2021 01:00 AM Genentech’s Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA)
Apr 13, 2021 08:30 AM Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies
Apr 13, 2021 08:30 AM Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform
Apr 12, 2021 01:20 PM  FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
View All Articles